Stada And Alvotech Launch Higher-Strength Adalimumab In Europe
Hukyndra Biosimilar To Humira Introduced In France, Germany, Finland And Sweden
Executive Summary
Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.
You may also be interested in...
Sandoz Launches High-Concentration Adalimumab In Europe
Sandoz has launched the high-concentration version of its Hyrimoz adalimumab biosimilar rival to Humira in Europe.
Alvotech And Stada Scoop First EU Stelara Biosimilar
Stada and Alvotech’s Uzpruvo ustekinumab biosimilar is set to become the EU’s first approved rival to Stelara after the EMA’s CHMP issued a positive opinion for the product. Meanwhile, the committee also endorsed a Lucentis biosimilar from Qilu Pharma as well as azacitidine and paclitaxel generics from Fresenius Kabi and Accord.
Alvotech And Bioventure Celebrate Egyptian Adalimumab Nod
Egypt has become the latest market in which Alvotech has received approval for its AVT02 biosimilar adalimumab rival to Humira. The product will be marketed by MENA partner Bioventure.